Receptor oligomerization and beyond: a case study in bone morphogenetic proteins

BackgroundTransforming growth factor (TGF)β superfamily members transduce signals by oligomerizing two classes of serine/threonine kinase receptors, termed type I and type II. In contrast to the large number of ligands only seven type I and five type II receptors have been identified in mammals, implicating a prominent promiscuity in ligand-receptor interaction. Since a given ligand can usually interact with more than one receptor of either subtype, differences in binding affinities and specificities are likely important for the generation of distinct ligand-receptor complexes with different signaling properties.ResultsIn vitro interaction analyses showed two different prototypes of binding kinetics, 'slow on/slow off' and 'fast on/fast off'. Surprisingly, the binding specificity of ligands to the receptors of one subtype is only moderate. As suggested from the dimeric nature of the ligands, binding to immobilized receptors shows avidity due to cooperative binding caused by bivalent ligand-receptor interactions. To compare these in vitro observations to the situation in vivo, binding studies on whole cells employing homodimeric as well as heterodimeric bone morphogenetic protein 2 (BMP2) mutants were performed. Interestingly, low and high affinity binding sites were identified, as defined by the presence of either one or two BMP receptor (BMPR)-IA receptor chains, respectively. Both sites contribute to different cellular responses in that the high affinity sites allow a rapid transient response at low ligand concentrations whereas the low affinity sites facilitate sustained signaling but higher ligand concentrations are required.ConclusionBinding of a ligand to a single high affinity receptor chain functioning as anchoring molecule and providing sufficient complex stability allows the subsequent formation of signaling competent complexes. Another receptor of the same subtype, and up to two receptors of the other subtype, can then be recruited. Thus, the resulting receptor arrangement can principally consist of four different receptors, which is consistent with our interaction analysis showing low ligand-receptor specificity within one subtype class. For BMP2, further complexity is added by the fact that heterooligomeric signaling complexes containing only one type I receptor chain can also be found. This indicates that despite prominent ligand receptor promiscuity a manifold of diverse signals might be generated in this receptor limited system.

[1]  W. Sebald,et al.  Functional epitope of common γ chain for interleukin-4 binding , 2002 .

[2]  N. Ueno,et al.  A Kinase Domain-truncated Type I Receptor Blocks Bone Morphogenetic Protein-2-induced Signal Transduction in C2C12 Myoblasts* , 1997, The Journal of Biological Chemistry.

[3]  W. Sebald,et al.  Cooperativity of Binding Epitopes and Receptor Chains in the BMP/TGFß Superfamily , 2001, Biological chemistry.

[4]  Kohei Miyazono,et al.  TGF-β signalling from cell membrane to nucleus through SMAD proteins , 1997, Nature.

[5]  S. Choe,et al.  Structure of the ternary signaling complex of a TGF-β superfamily member , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[6]  W. Sebald,et al.  Human bone morphogenetic protein 2 contains a heparin-binding site which modifies its biological activity. , 1996, European journal of biochemistry.

[7]  M. Sporn,et al.  Characterization of a membrane receptor for transforming growth factor-beta in normal rat kidney fibroblasts. , 1984, The Journal of biological chemistry.

[8]  W. Kwiatkowski,et al.  The BMP7/ActRII extracellular domain complex provides new insights into the cooperative nature of receptor assembly. , 2003, Molecular cell.

[9]  J. Pohl,et al.  Cloning and expression of recombinant human growth/differentiation factor 5. , 1994, Biochemical and biophysical research communications.

[10]  A. Kotzsch,et al.  A silent H-bond can be mutationally activated for high-affinity interaction of BMP-2 and activin type IIB receptor , 2007, BMC Structural Biology.

[11]  K. Miyazono,et al.  Cloning of a TGFβ type I receptor that forms a heteromeric complex with the TGFβ type II receptor , 1993, Cell.

[12]  T. Kirsch,et al.  Crystal structure of the BMP-2–BRIA ectodomain complex , 2000, Nature Structural Biology.

[13]  Y. Henis,et al.  Initiation of Smad-Dependent and Smad-Independent Signaling via Distinct BMP-Receptor Complexes , 2003, The Journal of bone and joint surgery. American volume.

[14]  C. Niehrs,et al.  Silencing of TGF-β signalling by the pseudoreceptor BAMBI , 1999, Nature.

[15]  S. Choe,et al.  A flexible activin explains the membrane-dependent cooperative assembly of TGF-beta family receptors. , 2004, Molecular cell.

[16]  F Layher,et al.  Osteointegration of hydroxyapatite-titanium implants coated with nonglycosylated recombinant human bone morphogenetic protein-2 (BMP-2) in aged sheep. , 2005, Bone.

[17]  A. Reddi,et al.  Bone morphogenetic proteins: an unconventional approach to isolation of first mammalian morphogens. , 1997, Cytokine & growth factor reviews.

[18]  K. Miyazono,et al.  Characterization of type I receptors for transforming growth factor-beta and activin. , 1994, Science.

[19]  J. Massagué,et al.  Novel activin receptors: Distinct genes and alternative mRNA splicing generate a repertoire of serine/threonine kinase receptors , 1992, Cell.

[20]  J. I. Izpisúa Belmonte,et al.  BMP-3 and BMP-6 structures illuminate the nature of binding specificity with receptors. , 2007, Biochemistry.

[21]  M. Alaoui-Ismaili,et al.  BMP-2/4 and BMP-6/7 Differentially Utilize Cell Surface Receptors to Induce Osteoblastic Differentiation of Human Bone Marrow-derived Mesenchymal Stem Cells* , 2008, Journal of Biological Chemistry.

[22]  K. Nakamura,et al.  p38 mitogen-activated protein kinase functionally contributes to chondrogenesis induced by growth/differentiation factor-5 in ATDC5 cells. , 1999, Experimental cell research.

[23]  A. Kotzsch,et al.  Crystal structure analysis reveals a spring‐loaded latch as molecular mechanism for GDF‐5–type I receptor specificity , 2009, The EMBO journal.

[24]  Anja Nohe,et al.  The Mode of Bone Morphogenetic Protein (BMP) Receptor Oligomerization Determines Different BMP-2 Signaling Pathways* , 2002, The Journal of Biological Chemistry.

[25]  A. Bradley,et al.  Cloning of the human activin receptor cDNA reveals high evolutionary conservation. , 1992, Biochimica et biophysica acta.

[26]  K. Miyazono,et al.  Cloning and characterization of a human type II receptor for bone morphogenetic proteins. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[27]  A. Waage,et al.  Bone morphogenetic protein-5, -6 and -7 inhibit growth and induce apoptosis in human myeloma cells , 2004, Oncogene.

[28]  T. Kirsch,et al.  BMP‐2 antagonists emerge from alterations in the low‐affinity binding epitope for receptor BMPR‐II , 2000, The EMBO journal.

[29]  K. Miyazono,et al.  Divergence and convergence of TGF‐β/BMP signaling , 2001, Journal of cellular physiology.

[30]  M. Kohno,et al.  Distribution and Characterization of Specific Cellular Binding Proteins for Bone Morphogenetic Protein-2 (*) , 1995, The Journal of Biological Chemistry.

[31]  Y. Henis,et al.  Different Routes of Bone Morphogenic Protein (BMP) Receptor Endocytosis Influence BMP Signaling , 2006, Molecular and Cellular Biology.

[32]  D. Kingsley,et al.  What do BMPs do in mammals? Clues from the mouse short-ear mutation. , 1994, Trends in genetics : TIG.

[33]  J. Massagué,et al.  TGF- SIGNAL TRANSDUCTION , 1998 .

[34]  T. Yamazaki,et al.  Identification of the ligand-binding site of the BMP type IA receptor for BMP-4. , 2000, Biopolymers.

[35]  Joachim Nickel,et al.  A single residue of GDF-5 defines binding specificity to BMP receptor IB. , 2005, Journal of molecular biology.

[36]  H. Shibai,et al.  Expression of erythroid differentiation factor (EDF) in Chinese hamster ovary cells. , 1988, Biochemical and biophysical research communications.

[37]  C. Woolf,et al.  Repulsive Guidance Molecule (RGMa), a DRAGON Homologue, Is a Bone Morphogenetic Protein Co-receptor* , 2005, Journal of Biological Chemistry.

[38]  A. Kotzsch,et al.  The solution structure of BMPR-IA reveals a local disorder-to-order transition upon BMP-2 binding. , 2008, Biochemistry.

[39]  K. Miyazono,et al.  Activin receptor-like kinases: a novel subclass of cell-surface receptors with predicted serine/threonine kinase activity. , 1993, Oncogene.

[40]  J. Massagué,et al.  Human type II receptor for bone morphogenic proteins (BMPs): extension of the two-kinase receptor model to the BMPs , 1995, Molecular and cellular biology.

[41]  N. Ueno,et al.  Interaction between Soluble Type I Receptor for Bone Morphogenetic Protein and Bone Morphogenetic Protein-4* , 1997, The Journal of Biological Chemistry.

[42]  J. Massagué TGF-beta signal transduction. , 1998, Annual review of biochemistry.

[43]  Roland Baron,et al.  BMP‐2 Controls Alkaline Phosphatase Expression and Osteoblast Mineralization by a Wnt Autocrine Loop , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[44]  W. Sebald,et al.  Molecular recognition of BMP-2 and BMP receptor IA , 2004, Nature Structural &Molecular Biology.

[45]  F. Lallemand,et al.  Activation of mitogen-activated protein kinase cascades is involved in regulation of bone morphogenetic protein-2-induced osteoblast differentiation in pluripotent C2C12 cells. , 2001, Bone.

[46]  A. Reddi,et al.  Identification and characterization of cellular binding proteins (receptors) for recombinant human bone morphogenetic protein 2B, an initiator of bone differentiation cascade. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[47]  J. Massagué,et al.  Identification of human activin and TGFβ type I receptors that form heteromeric kinase complexes with type II receptors , 1993, Cell.

[48]  T. Hage,et al.  Global and Local Determinants for the Kinetics of Interleukin‐4/Interleukin‐4 Receptor α Chain Interaction , 1996 .

[49]  J. L. Rosa,et al.  JunB Is Involved in the Inhibition of Myogenic Differentiation by Bone Morphogenetic Protein-2* , 1998, The Journal of Biological Chemistry.

[50]  A. Kotzsch,et al.  Type I receptor binding of bone morphogenetic protein 6 is dependent on N‐glycosylation of the ligand , 2008, The FEBS journal.

[51]  T. Hage,et al.  Global and local determinants for the kinetics of interleukin-4/interleukin-4 receptor alpha chain interaction. A biosensor study employing recombinant interleukin-4-binding protein. , 1996, European journal of biochemistry.

[52]  K. Miyazono,et al.  Signal transduction by bone morphogenetic proteins. , 1998, Cytokine & growth factor reviews.

[53]  A. Reddi,et al.  Role of morphogenetic proteins in skeletal tissue engineering and regeneration , 1998, Nature Biotechnology.

[54]  D. Goldenberg,et al.  Evaluation of a remote radioiodination system for radioimmunotherapy. , 1990, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[55]  K. Miyazono,et al.  Identification of Type I and Type II Serine/Threonine Kinase Receptors for Growth/Differentiation Factor-5* , 1996, The Journal of Biological Chemistry.

[56]  B. Hogan,et al.  Bone morphogenetic proteins: multifunctional regulators of vertebrate development. , 1996, Genes & development.

[57]  H. Beppu,et al.  Repulsive Guidance Molecule RGMa Alters Utilization of Bone Morphogenetic Protein (BMP) Type II Receptors by BMP2 and BMP4* , 2007, Journal of Biological Chemistry.

[58]  John C. Lee,et al.  Characterization of ligand-binding properties of the human BMP type II receptor extracellular domain. , 2008, Journal of molecular biology.

[59]  Charles C Hong,et al.  Dorsomorphin inhibits BMP signals required for embryogenesis and iron metabolism. , 2008, Nature chemical biology.

[60]  T. Kirsch,et al.  Isolation of recombinant BMP receptor IA ectodomain and its 2:1 complex with BMP‐2 , 2000, FEBS letters.

[61]  T. Jardetzky,et al.  Structures of an ActRIIB:activin A complex reveal a novel binding mode for TGF‐β ligand:receptor interactions , 2003, The EMBO journal.

[62]  Joachim Nickel,et al.  Structure Analysis of Bone Morphogenetic Protein-2 Type I Receptor Complexes Reveals a Mechanism of Receptor Inactivation in Juvenile Polyposis Syndrome* , 2008, Journal of Biological Chemistry.

[63]  Guang-Quan Zhao,et al.  Consequences of knocking out BMP signaling in the mouse , 2003, Genesis.